Study guide

10.9 Electrolyte Imbalances and Dysrhythmia Risk

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

10.9 Electrolyte Imbalances and Dysrhythmia Risk

Key Takeaways Explain This Topic AI

In hyperkalemia the sequence is fixed: IV calcium first for membrane stabilization (onset 1-3 minutes, lasts 30-60 minutes), then insulin 10 units with 25 g dextrose and nebulized albuterol 10-20 mg to shift potassium, then binders or dialysis for true removal.

Hypokalemia is refractory until magnesium is corrected; peripheral potassium infusion is limited to about 10 mEq/h and central infusion to about 20 mEq/h, and every 10 mEq raises serum potassium roughly 0.1 mEq/L.

Torsades de pointes is treated with magnesium sulfate 1-2 g IV regardless of the serum magnesium level, plus overdrive pacing to 90-110/min for recurrent episodes.

Calcium chloride 10% delivers about 272 mg of elemental calcium per 10 mL versus about 93 mg for calcium gluconate 10% - roughly three times the calcium, but chloride is a vesicant requiring central access.

Sodium correction is capped at 8 mEq/L per 24 hours to prevent osmotic demyelination; a QTc above 500 ms or an increase of more than 60 ms from baseline requires action.

Last updated: August 2026

Why Electrolytes Are a Rhythm Problem

Test-plan item II.E.3 is examined almost entirely through the monitor. Every cardiac myocyte's action potential depends on transmembrane ion gradients, so an electrolyte shift is a change in the resting membrane potential, the rate of phase 0 depolarization, or the duration of repolarization — which is to say, a change in the ECG and in arrhythmia risk. On a cardiac unit the derangements are largely iatrogenic : loop diuretics waste potassium and magnesium, aggressive decongestion produces contraction alkalosis, RAAS inhibitors and mineralocorticoid receptor antagonists retain potassium, and the antiarrhythmics we use prolong the QT. The nurse who checks the magnesium before escalating potassium replacement, or who recognizes a QTc creeping past 500 ms on a sotalol load, prevents the arrest.

The Reference Table

  • Electrolyte Adult reference range
  • Potassium 3.5–5.0 mEq/L (cardiac patients are often targeted at 4.0–5.0)
  • Magnesium 1.7–2.2 mg/dL (about 1.5–2.5 mEq/L); cardiac targets are often 2.0 or above
  • Total calcium 8.5–10.5 mg/dL; ionized calcium 1.1–1.3 mmol/L (about 4.5–5.3 mg/dL)
  • Sodium 135–145 mEq/L
  • Phosphate 2.5–4.5 mg/dL
  • Potassium
  • Hyperkalemia

Causes on a cardiac unit: acute kidney injury and CKD, ACE inhibitors, ARBs, sacubitril-valsartan, spironolactone and eplerenone, potassium-sparing diuretics, trimethoprim-sulfamethoxazole and heparin (both suppress aldosterone effect), beta blockers, tissue breakdown from rhabdomyolysis or hemolysis on mechanical circulatory support, massive transfusion, and metabolic acidosis. Always ask whether the value is pseudohyperkalemia from a hemolyzed sample, a tight tourniquet with fist-clenching, or marked leukocytosis or thrombocytosis — but never delay treating a patient with ECG changes while you wait for a redraw.

ECG progression — memorize the order:

Peaked, narrow-based, symmetric T waves (roughly 5.5–6.5 mEq/L), tallest in the precordial leads.

PR prolongation and P-wave flattening , then loss of the P wave (6.5–7.5).

QRS widening into a bizarre, non-specific intraventricular conduction delay (7.0–8.0).

Sine wave — the widened QRS merges with the T wave (above 8.0).

Ventricular fibrillation or asystole.

The emergency sequence:

Step Agent and dose Onset / duration Point

1. Stabilize the membrane Calcium gluconate 1–2 g (10–20 mL of 10%) IV over 2–5 minutes via a peripheral line, or calcium chloride 1 g (10 mL of 10%) via central line 1–3 minutes / 30–60 minutes Does not lower potassium — it raises the threshold potential and restores the gradient. Repeat if ECG changes persist after 5 minutes. In suspected digoxin toxicity give calcium slowly and diluted, and treat the real problem with digoxin immune Fab

2. Shift intracellularly Regular insulin 10 units IV with 25 g dextrose (50 mL of D50) unless glucose is above 250 mg/dL 15–30 minutes / 4–6 hours Lowers potassium 0.5–1.2 mEq/L. Recheck glucose hourly for at least 6 hours ; use 5 units in CKD or low body weight because hypoglycemia is the commonest complication

3. Shift intracellularly Albuterol 10–20 mg nebulized over 10 minutes (4–8 times the bronchodilator dose) 30 minutes / 2–4 hours Lowers potassium 0.5–1.0 mEq/L; additive with insulin. Expect tachycardia and tremor — use cautiously in active ischemia

4. Remove Loop diuretic if urine output is present; sodium zirconium cyclosilicate 10 g three times daily for 48 hours (onset about 1 hour) or patiromer 8.4 g daily (onset 7 hours); hemodialysis is definitive Variable Only these actually take potassium out of the body. Sodium polystyrene sulfonate is largely abandoned because of colonic necrosis risk

Weak option Sodium bicarbonate Slow, unreliable Useful only as an adjunct in significant metabolic acidosis; it is not a primary agent and adds a sodium and volume load the cardiac patient does not need

Hypokalemia

Causes: loop and thiazide diuretics (the dominant cause in cardiology), GI losses, insulin and beta-2 agonists driving potassium intracellularly, alkalosis, hypomagnesemia, hyperaldosteronism, and refeeding.

ECG: ST-segment depression, T-wave flattening then inversion, prominent U waves , and apparent QT prolongation that is really a fused QU interval . Consequences: increased automaticity, PVCs, atrial and ventricular tachycardia, torsades, and marked potentiation of digoxin toxicity .

Replacement rules:

Every 10 mEq of potassium raises the serum level about 0.1 mEq/L — total body deficit is far larger than the serum number suggests (a serum potassium of 3.0 mEq/L reflects a deficit of roughly 200–400 mEq).

Peripheral infusion: no more than 10 mEq/h at a concentration no greater than 10 mEq per 100 mL. Faster or more concentrated infusion causes phlebitis and severe pain.

Central infusion: up to 20 mEq/h with continuous ECG monitoring; rates up to 40 mEq/h are reserved for life-threatening hypokalemia with arrhythmia under direct monitoring.

Correct magnesium first. Hypomagnesemia removes the inhibition on renal outer medullary potassium channels, so the kidney dumps every milliequivalent you give. Hypokalemia that will not correct is hypomagnesemia until proven otherwise — this is the single most tested electrolyte relationship on the CMC.

Target 4.0–5.0 mEq/L in acute myocardial infarction, heart failure and any patient with ventricular ectopy; recheck 1–2 hours after an IV dose.

Watch for rebound hyperkalemia in patients on RAAS inhibitors or with AKI.